Meanwhile, according to a 2026 study, patients in the dataset who took Wegovy were 4.74 times more likely to develop ION (Ischemic optic neuropathy) than those who took another brand of GLP-1 drugs
Molecular mechanisms regulating hair follicle development
Meet our doctors Last reviewed: 19 Jun 2026 Sources Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity, Diabetes, Obesity and Metabolism, [accessed 14 January 2026] Transdermal drug delivery: overcoming the skin's barrier function, Europe PMC [accessed 14 January 2026] (D) Routes of delivery: Case studies: (6) Transdermal delivery of peptides and proteins, Advanced Drug Delivery Reviews, [accessed 14 January 2026] Semaglutide for the treatment of overweight and obesity: A review, Diabetes, Obesity and Metabolism, [accessed 14 January 2026] Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK, [accessed 14 January 2026]
consider reducing doses of these medications when initiating tirzepatide Signs of acute kidney injury, particularly in patients experiencing severe gastrointestinal adverse effects with dehydration Symptoms of pancreatitis (severe abdominal pain radiating to the back, nausea, vomiting) Gallbladder disease (right upper quadrant pain, fever, jaundice) Gastrointestinal adverse effects, which occur commonly but are usually self-limited Tirzepatide is not recommended for patients with severe gastrointestinal disease, including severe gastroparesis
